Intentional human dosing studies for EPA regulatory purposes : scientific and ethical issues / Committee on the Use of Third Party Toxicity Research with Human Research Participants, Science, Technology, and Law Program, Policy and Global Affairs Division, National Research Council of the National Academies.

Format:

Book

Contributor:

National Research Council (U.S.). Policy and Global Affairs.

National Research Council (U.S.). Committee on the Use of Third Party Toxicity Research with Human Research Participants.

Language:

English

Subjects (All):

United States. Environmental Protection Agency.

United States.

Human experimentation in medicine--Moral and ethical aspects.

Human experimentation in medicine.

Human experimentation in medicine--Government policy--United States.

Medical ethics.

Medicine--Research--Moral and ethical aspects.

Medicine.

Physical Description:

1 online resource (226 p.)

Edition:

1st ed.

Place of Publication:

Washington, D.C. : National Academies Press, c2004.

Language Note:

English

Summary:

The EPA commissioned The National Academies to provide advice on the vexing question of whether and, if so, under what circumstances EPA should accept and consider intentional human dosing studies conducted by companies or other sources outside the agency (so-called third parties) to gather evidence relating to the risks of a chemical or the conditions under which exposure to it could be judged safe. This report recommends that such studies be conducted and used for regulatory purposes only if all of several strict conditions are met, including the following: The study is necessary and scientifically valid, meaning that it addresses an important regulatory question that can (TM)t be answered with animal studies or nondosing human studies; The societal benefits of the study outweigh any anticipated risks to participants. At no time, even when benefits beyond improved regulation exist, can a human dosing study be justified that is anticipated to cause lasting harm to study participants; and All recognized ethical standards and procedures for protecting the interests of study participants are observed. In addition, EPA should establish a Human Studies Review Board (HSRB) to evaluate all human dosing studies " both at the beginning and upon completion of the experiments " if they are carried out with the intent of affecting the agency's policy-making.

Contents:

FrontMatter

Acknowledgments

Preface

Contents

List of Tables and Boxes

Acronyms

Executive Summary and Recommendations

1 Introduction and Background

2 The Regulatory Framework for Protecting Humans in Research

3 Scientific Justification for and Conduct of Intentional Human Dosing Studies

4 A Risk-Benefit Framework for Assessing Intentional Human Dosing Studies

5 Ethical Considerations in the Review of Intentional Human Dosing Studies

6 Procedures for EPA Review of Intentional Human Dosing Studies

7 EPA's Use of Data from Intentional Human Dosing Studies in Risk Assessment

APPENDIXES

Appendix A Values and Limitations of Animal Toxicity Data

Appendix B Pharmacokinetics and Metabolism of Pesticides

Appendix C Biographical Sketches of the Members and Staff of the Committee on the Use of Third Party Toxicity Research with Human Research Participants

Appendix D Biographical Sketches of the Members of the Science, Technology, and Law Panel

Appendix E Meeting Agendas

Appendix F Combined Registrants List for All Meetings.

Notes:

Bibliographic Level Mode of Issuance: Monograph

Includes bibliographical references.

ISBN:

9786610176298

9780309166416

0309166411

9781280176296

1280176296

9780309530989

0309530989

OCLC:

70772941